Inflammatory bowel disease (IBD) is characterized by chronic
inflammation of the gastrointestinal tract. It is unknown whether β-1,3;1,6-
glucan can induce immune suppressive effects. Here, we study intestinal anti-inflammatory activity of Lentinula edodes-derived β-1,3;1,6-
glucan, which is known as
lentinan.
Dextran sulfate sodium (DSS)-induced
colitis mice were used to elucidate effects of
lentinan in vivo. In the cellular level assessment,
lentinan was added into a co-culture model consisting of intestinal epithelial Caco-2 cells and LPS-stimulated macrophage RAW264.7 cells. Ligated intestinal loop assay was performed for assessing effects of
lentinan on intestinal epithelial cells (IECs) in vivo.
Oral administration of
lentinan (100 µg/mouse) significantly ameliorated DSS-induced
colitis in
body weight loss, shortening of colon lengths, histological score, and inflammatory
cytokine mRNA expression in inflamed tissues.
Lentinan reduced
interleukin (IL)-8
mRNA expression and nuclear factor (NF)-κB activation in Caco-2 cells without decreasing of
tumor necrosis factor (TNF)-α production from RAW264.7 cells. Flow cytometric analysis revealed that surface levels of
TNF receptor (TNFR) 1 were decreased by
lentinan treatment. A
clathrin-mediated endocytosis inhibitor,
monodansylcadaverine, canceled
lentinan inhibition of
IL-8 mRNA expression. Moreover,
lentinan inhibited
TNFR1 expression in Caco-2 cells in both
protein and
mRNA level.
Lentinan also inhibited
TNFR1 mRNA expression in mouse IECs. These results suggest that
lentinan exhibits intestinal anti-inflammatory activity through inhibition of
IL-8 mRNA expression associated with the inhibition of NF-κB activation which is triggered by
TNFR1 endocytosis and lowering of their expression in IECs.
Lentinan may be effective for the treatment of gut
inflammation including IBD.